Bruce Yacyshyn

5.4k total citations · 1 hit paper
78 papers, 3.5k citations indexed

About

Bruce Yacyshyn is a scholar working on Genetics, Epidemiology and Immunology. According to data from OpenAlex, Bruce Yacyshyn has authored 78 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Genetics, 23 papers in Epidemiology and 18 papers in Immunology. Recurrent topics in Bruce Yacyshyn's work include Inflammatory Bowel Disease (31 papers), Microscopic Colitis (20 papers) and Cell Adhesion Molecules Research (13 papers). Bruce Yacyshyn is often cited by papers focused on Inflammatory Bowel Disease (31 papers), Microscopic Colitis (20 papers) and Cell Adhesion Molecules Research (13 papers). Bruce Yacyshyn collaborates with scholars based in United States, Canada and France. Bruce Yacyshyn's co-authors include William J. Sandborn, Mary Beth Bowen-Yacyshyn, William Shanahan, Mary Beth Yacyshyn, Jon Meddings, Piotr Krzeski, Brian G. Feagan, Stephen B. Hanauer, Simon Travis and Dan Schnell and has published in prestigious journals such as SHILAP Revista de lepidopterología, The Journal of Immunology and Gastroenterology.

In The Last Decade

Bruce Yacyshyn

73 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)

2011 441 citations Simon Travis, Dan Schnell et al. Gut profile →

Peers

Countries citing papers authored by Bruce Yacyshyn

Since Specialization

Citations

This map shows the geographic impact of Bruce Yacyshyn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruce Yacyshyn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruce Yacyshyn more than expected).

Fields of papers citing papers by Bruce Yacyshyn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bruce Yacyshyn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruce Yacyshyn. The network helps show where Bruce Yacyshyn may publish in the future.

Co-authorship network of co-authors of Bruce Yacyshyn

This figure shows the co-authorship network connecting the top 25 collaborators of Bruce Yacyshyn. A scholar is included among the top collaborators of Bruce Yacyshyn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bruce Yacyshyn. Bruce Yacyshyn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Feasibility study of Bismuth Subsalicylate (BSS) as an addition to standard of care for COVID-19 therapy 2022 ·Current Therapeutic Research ·Mary Beth Yacyshyn, James K. Collins, (unknown), (unknown), (unknown), (unknown), Bruce Yacyshyn	1
2	Systematic Review and Meta-Analyses Assessment of the Clinical Efficacy of Bismuth Subsalicylate for Prevention and Treatment of Infectious Diarrhea 2020 ·Digestive Diseases and Sciences ·José M. Brum, Roger Gibb, (unknown), (unknown), Bruce Yacyshyn	15
3	Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis 2019 ·Gastroenterology ·William J. Sandborn, Laurent Peyrin‐Biroulet, Jinkun Zhang, Michael Chiorean, Séverine Vermeire, Scott D. Lee, Tanja Kühbacher, Bruce Yacyshyn, Christopher H. Cabell, Snehal Naik, Preston Klassen, Julián Panés	175
4	Canonical Wnt Signaling Ameliorates Aging of Intestinal Stem Cells 2017 ·Cell Reports ·Kodandaramireddy Nalapareddy, Kalpana Nattamai, Rupali Kumar, Rebekah Karns, Kathryn A. Wikenheiser‐Brokamp, Leesa Sampson, Maxime M. Mahé, Nambirajan Sundaram, (unknown), Bruce Yacyshyn, Michael A. Helmrath, Yi Zheng, Hartmut Geiger	177
5	Reliability and Initial Validation of the Ulcerative Colitis Endoscopic Index of Severity 2013 ·Gastroenterology ·Simon Travis, Dan Schnell, Piotr Krzeski, María T. Abreu, Douglas G. Altman, Jean–Frédéric Colombel, Brian G. Feagan, Stephen B. Hanauer, Gary R. Lichtenstein, Philippe Marteau, Walter Reinisch, Bruce E. Sands, Bruce Yacyshyn, Patrick Schnell, Christian A. Bernhardt, Jean–Yves Mary, William J. Sandborn	328
6	Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) breakdown → 2011 ·Gut ·Simon Travis, Dan Schnell, Piotr Krzeski, María T. Abreu, Douglas G. Altman, Jean–Frédéric Colombel, Brian G. Feagan, Stephen B. Hanauer, Marc Lémann, Gary R. Lichtenstein, (unknown), Walter Reinisch, Bruce E. Sands, Bruce Yacyshyn, Christian A. Bernhardt, Jean–Yves Mary, William J. Sandborn	441
7	Delayed-Release Oral Mesalamine 4.8 g/day (800-mg Tablet) Is Effective for Patients With Moderately Active Ulcerative Colitis 2009 ·Gastroenterology ·William J. Sandborn, Jarosław Reguła, Brian G. Feagan, E. А. Belousova, (unknown), Milan Lukáš, Bruce Yacyshyn, Piotr Krzeski, (unknown), (unknown), Stephen B. Hanauer	119
8	Adhesion molecule therapeutics in IBD 2008 ·Inflammatory Bowel Diseases ·Bruce Yacyshyn	7
9	A Randomized, Double-Masked, Placebo-Controlled Study of Alicaforsen, an Antisense Inhibitor of Intercellular Adhesion Molecule 1, for the Treatment of Subjects With Active Crohn’s Disease 2007 ·Clinical Gastroenterology and Hepatology ·Bruce Yacyshyn, William Y. Chey, Mark K. Wedel, Rosie Z. Yu, David A. Paul, Emil Chuang	98
10	The Clinical Importance of Proton Pump Inhibitor Pharmacokinetics 2002 ·Digestion ·Bruce Yacyshyn, A. B. R. Thomson	42
11	Dose ranging pharmacokinetic trial of high‐dose alicaforsen (intercellular adhesion molecule‐1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease 2002 ·Alimentary Pharmacology & Therapeutics ·Bruce Yacyshyn, Charles F. Barish, J S Goff, (unknown), (unknown), Rosie Z. Yu, J. Tami, F. Andrew Dorr, K. Lea Sewell	55
12	Critical Review of Acid Suppression in Nonvariceal, Acute, Upper Gastrointestinal Bleeding 2000 ·Digestive Diseases ·Bruce Yacyshyn, A. B. R. Thomson	17
13	Preclinical and Clinical Pharmacology of Antisense Oligonucleotides 1999 ·Molecular Biotechnology ·Eric G. Marcusson, Bruce Yacyshyn, William Shanahan, Nicholas M. Dean	30
14	Differences in P-glycoprotein-170 expression and activity between Crohn’s disease and ulcerative colitis 1999 ·Human Immunology ·Bruce Yacyshyn, Walter P. Maksymowych, Mary Beth Bowen-Yacyshyn	39
15	New Biotechnological Therapies for Crohn??s Disease 1998 ·BioDrugs ·Bruce Yacyshyn	2
16	A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease 1998 ·Gastroenterology ·Bruce Yacyshyn, Mary Beth Bowen-Yacyshyn, Lawrence D. Jewell, Joseph A. Tami, C. Frank Bennett, Daniel L. Kisner, William Shanahan	295
17	Multiple sclerosis patients have peripheral blood CD45RO+ B cells and increased intestinal permeability 1996 ·Digestive Diseases and Sciences ·Bruce Yacyshyn, Jon Meddings, Daniel Sadowski, Mary Beth Bowen-Yacyshyn	79
18	Inhibition by Rapamycin of P‐Glycoprotein 170‐Mediated Export from Normal Lymphocytes 1996 ·Scandinavian Journal of Immunology ·Bruce Yacyshyn, Mary Beth Bowen-Yacyshyn, L M Pilarski	32
19	Crohn's disease, ulcerative colitis, and normal intestinal lymphocytes express integrins in dissimilar patterns 1994 ·Gastroenterology ·Bruce Yacyshyn, Andrew I. Lazarovits, (unknown), (unknown)	36
20	Activated CD19⁺ B cell lamina propria lymphocytes in ulcerative colitis 1993 ·Immunology and Cell Biology ·Bruce Yacyshyn	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact